Proving the Business Case for the Internet of Things

Savsu smart shipping container helps track biological payloads

Steve Rogerson
June 30, 2015
 
New Mexico-based Savsu Technologies demonstrated its Evo smart shipping container at the International Society for Cellular Therapy Conference in Las Vegas. Savsu is a partner in a joint venture with Washington-based BioLife Solutions, a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud-hosted biologistics cold chain management app for smart shippers.
 
Savsu designs and manufactures passive storage and transport containers for temperature sensitive biologics and pharmaceuticals.
 
The Evo precision thermal shipper and its cloud hosted Biologistex application enable customers to pack, ship and track high-value biologic payloads in real time, reducing the need for expensive courier services.
 
New cellular therapies and regenerative medicines used to treat disease require strict temperature ranges during storage and transport to ensure their viability. The Evo's ability to monitor and report on biologic payload conditions including internal and external temperature, light, humidity, shock, and pressure help users make sure these critical environments are maintained during shipping. The app enables users to configure text and email alerts on location, delivery, unpacking and remaining stability time.
 
The product line and integrated cloud hosted data management system expand on Savsu's expertise in designing shipping and storage containers for temperature sensitive biologic materials. Three Evo models demonstrated at the conference are for 2 to 8ËšC, CRT and frozen shipments.
 
"Our new Evo product line is the hardware component of the product offering from our Biologistex joint venture," said Bruce McCormick, president of Savsu Technologies. “It represents our latest thinking about shipping critical, small volume cellular therapies and tissue samples, which are more difficult than large volume shipments. In case of autologous therapies, we all know there is a patient depending on a customised cellular therapy to arrive safely and reliably. That was terrific motivation to help create a system that advances the state of the art significantly.”